Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTavistock Regulatory News (TAVI)

Share Price Information for Tavistock (TAVI)

Share Price is delayed by 15 minutes
Get Live Data
3.15    0.00 (0.00%)
Bid:
3.00
Ask:
3.30
Spread: 0.30 (10.00%)
Market Cap: £13.89m
TAVI Live PriceLast checked at - London Stock Exchange

Intraday Tavistock Share Chart

Trading Update

8 Apr 2020 07:00

RNS Number : 0917J
Tavistock Investments PLC
08 April 2020
 

Tavistock Investments Plc

("Tavistock" or the "Company")

Trading Update

8th April 2020

The Company is pleased to advise that its trading result for the year ended 31 March 2020 is expected to be in line with the market's expectation for continued growth in reported EBITDA.

One particular highlight of the year has been the superb performance of the Company's new range of protected UCITS funds. They were designed specifically to shield clients from the potentially disastrous consequences of sudden and sustained falls in market values, offering investors an alternative, more prudent approach to medium to long term investing.

The ACUMEN Capital Protection Portfolio and the ACUMEN ESG Protection Portfolio provide a guaranteed level of protection for investors equivalent to 90% of each fund's highest ever value (Net Asset Value or NAV). These guarantees are contractually underwritten by Morgan Stanley & Co International Plc.

By way of illustration, between 1st January and 31st March 2020, the FTSE fell 24%. By contrast, these two protected funds fell by less than 5% and 3% respectively.

As of Monday, an investment made in the ACUMEN Capital Protection Portfolio risked a maximum potential loss of only 3.6% of the initial investment, whilst still benefiting from the 90% high watermark guarantee going forward.

However, the COVID-19 pandemic has caused commercial conditions to become extremely challenging. It is inevitable that adverse economic and market performance, together with the commercial consequences of social distancing and the Government imposed lock-down, will combine to have a detrimental effect on the Company's performance in the new financial year. The impact of the pandemic will be felt for some considerable time, potentially through several iterations, and at the moment it is impossible to accurately assess the consequences.

In light of this uncertainty, the Board has adopted a number of measures to protect profitability and ensure that the business emerges from the current crises in the best working order. No dividend will be paid at the present time and a comprehensive strategic review is also being undertaken with a view to removing cost from the business. This exercise will encompass a pragmatic impairment review of the carrying value of intangible assets on the Company's Balance Sheet.

Every member of the executive team has volunteered to waive a significant proportion of their income, with immediate effect, so that everyone in the business understands that we will deal with the challenges ahead together.

Pending stability in the financial markets, the Company has withdrawn its guidance for market expectation in the year to 31 March 2021.

Brian Raven, the Company's Chief Executive, said:

"The key measure of leadership is how well it performs under difficult circumstances. Tavistock is led by a strong, experienced and unified team who have clearly demonstrated their commitment to the business and its staff.

We continue to look after the financial advice needs of our tens of thousands of underlying clients, and to manage their assets in our customary active, efficient and disciplined manner.

Market turbulence is far from over and a potentially very deep recession lies ahead.

A great many clients, particularly the less well off, cannot afford to risk further significant losses to savings or pension pots. These clients need security, ahead of investment upside potential. I believe that Tavistock's ACUMEN Protection Portfolios offer a safe haven solution for these cautious investors in these very difficult times. Whilst the funds primary purpose is to protect the downside, they will also be automatically, but gradually, reinvested from cash into higher risk assets, as market volatility reduces."

 

Ends

 

Enquiries

Tavistock Investments Plc

Oliver Cooke

Brian Raven

Tel: 01753 867000

 

Arden Partners Plc

Paul Shackleton

Tel: 020 7614 5900

Allenby Capital Limited

Nick Naylor

Nick Athanas

Tel: 020 3328 5656

Vested

Elspeth Rothwell

Tel: 020 3890 8118

 

(Mobile): 07811 375 998

Amelia Graham

(Mobile): 07393 477 057

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFLFEFSEIDIII
Date   Source Headline
29th May 20269:00 amRNSDirectorate Change
2nd Apr 20267:00 amRNSCompletion of Acquisition
30th Mar 20262:55 pmRNSChange of Auditor
5th Feb 20267:00 amRNSFurther Update on Litigation with Titan
20th Jan 20267:00 amRNSAppointment of Nominated Adviser and Broker
23rd Dec 20257:00 amRNSInterim Results
23rd Dec 20257:00 amRNSInterim Results
17th Dec 202512:13 pmRNSFurther update re ongoing litigation with Titan
16th Dec 20257:00 amRNSUpdate re ongoing litigation with Titan
6th Nov 202512:00 pmRNSResult of AGM
2nd Oct 20257:00 amRNSUpdate re ongoing litigation
30th Sep 20255:00 pmRNSTotal Voting Rights
30th Sep 20257:00 amRNSNotice of AGM
25th Sep 20257:00 amRNSTransfer of Shares from treasury to EBT and TVR
24th Sep 202510:57 amRNSDirector/PDMR Shareholding
18th Sep 20257:00 amRNSFinal Results for the Year Ended 31 March 2025
15th Sep 20252:08 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSStrategic refocus and acquisition of Lifetime
7th Jul 202512:40 pmRNSDirector / PDMR Dealing
8th Apr 20254:15 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20255:00 pmRNSTotal Voting Rights
20th Feb 20257:00 amRNSCompletion of acquisition of Alpha Beta Partners
14th Feb 202512:08 pmRNSDirector/PDMR Shareholding
11th Feb 20257:00 amRNSTransaction in Own Shares,Director Dealing and TVR
6th Feb 20252:16 pmRNSDirector/PDMR Shareholding
30th Jan 202511:00 amRNSHolding(s) in Company
30th Jan 20259:53 amRNSHolding(s) in Company
6th Jan 202511:54 amRNSHolding(s) in Company
2nd Jan 20255:45 pmRNSTotal Voting Rights - Replacement
31st Dec 20241:30 pmRNSTotal Voting Rights
12th Dec 202412:00 pmRNSTransaction in Own Shares and Total Voting Rights
11th Dec 202411:30 amRNSResult of AGM
9th Dec 202412:49 pmRNSTransaction in Own Shares and Total Voting Rights
9th Dec 20247:00 amRNSInterim Results
2nd Dec 20247:00 amRNSRepositioning of Retail Asset Management business
22nd Nov 20247:00 amRNSStrategic acquisition and completion of disposal
11th Nov 20243:38 pmRNSNotice of AGM
30th Oct 202411:25 amRNSResult of General Meeting
2nd Oct 20243:50 pmRNSPublication of Circular and Notice of GM
2nd Oct 202411:32 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSProposed disposals for up to £37.75 million
30th Sep 20247:00 amRNSFinal Results for the Year Ended 31 March 2024
19th Sep 20242:47 pmRNSUpdate on Titan Dispute
11th Jul 20247:00 amRNSFollow up to Titan termination announcement
8th Jul 20244:19 pmRNSTermination of strategic partnership
28th Jun 202410:16 amRNSStatement re press speculation
21st Jun 202410:31 amRNSDirectorate Change
31st May 20247:00 amRNSBoard role change
8th Jan 20247:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.